Endothelin 1 and pathophysiology of pulmonary hypertension;Endothéline-1 et physiopathologie de l'hypertension artérielle pulmonaire

Revue des Maladies Respiratoires

Volumn 20, Issue 5 II, 2003, Pages

  Dinh Xuan, A T ^a  

^a Hôpital Cochin ^*  (France)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTHELIN 1;

ADULT RESPIRATORY DISTRESS SYNDROME; ALCOHOLISM; CONFERENCE PAPER; HUMAN; LUNG FUNCTION; MULTIPLE ORGAN FAILURE; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PULMONARY HYPERTENSION; SCREENING TEST;

EID: 18544397408     PISSN: 07618425     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (17)

1. Dinh-Xuan AT: Disorders of endothelium-dependent relaxation in pulmonary disease. Circulation 1993; 87 (Suppl V): V81-7.
2. Loscalzo J: Endothelial dysfunction in pulmonary hypertension. N Engl J Med 1992; 327: 117-9.
3. Dinh-Xuan AT: Endothelial modulation of pulmonary vascular tone. Eur Respir J 1992; 5: 757-62.
4. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K, Masaki T: A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988; 332: 411-5.
5. Huggins JP, Pelton JT, Miller RC: The structure and specificity of endothelin receptors: their importance in physiology and medicine. Pharmacol Therapeut 1993; 59: 55-123.
6. Zellers TM, McCormick J, Wu Y: Interaction among ET-1, endothelium-derived nitric oxide, and prostacyclin in pulmonary arteries and veins. Am J Physiol Heart Circ Physiol 1994; 267: H139-147.
7. Hasunuma K, Rodman DM, O'Brien RF, McMurtry IF: Endothelin-1 causes pulmonary vasodilation in rats. Am J Physiol Heart Circ Physiol 1990; 259: H48-54.
8. Sabry S, Mondon F, Lévy M, Ferré F, Dinh-Xuan AT: Endothelial modulation of vasoconstrictor responses to endothelin-1 in human placental stem villi small arteries. Br J Pharmacol 1995; 115: 1038-42.
9. McMurdo L, Corder R, Thiermermann C, Vane JR: Incomplete inhibition of the pressor effects of endothelin-1 and related peptides in the anaesthetized rat with BQ-123 provides evidence for more than one vasoconstrictor receptor. Br J Pharmacol 1993; 108: 557-61.
10. Sakurai T, Goto K: Endothelins: vascular actions and clinical implications. Drugs 1993; 46: 795-804.
11. Giaid A, Yanagisawa M, Langleben D, Michel RP, Levy R, Shennib H, Kimura S, Masaki T, Duguid W, Stewart DJ: Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 1993; 238: 1732-9.
12. Sanchez O, Fadel E, Humbert M, Capron F, Dartevelle P, Simonneau G, Adnot S, Eddahibi S: Endothelin-1 synthesis and function in pulmonary artery smooth muscle cells from patients with primary pulmonary hypertension. Am J Respir Crit Care Med 2003; 167: A695.
13. Rubin LJ, Badesch DB, Barst RJ, Gali N, Black CM, Keogh A, Pulido T, Frost A, Roux S, Leconte I, Landzberg M, Simonneau G: The bosentan randomized trial of endothelin antagonist therapy study group: Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002; 346: 896-903.
14. Schoene AM, Lossnitzer D, Szalai PS, Meyer FJ, Borst MM: B-type natriuretic peptide serum levels before and during bosentan therapy in patients with pulmonary arterial hypertension: relation to clinical data. Am J Respir Crit Care Med 2003; 167: A441.
15. Sulica R, DePalo L, Russo E, Poon M. Therapeutic effect of Bosentan in the treatment of pulmonary hypertension from various etiologies. Am J Respir Crit Care Med 2003; 167: A274.
16. Hoeper MM, Taha N, Gatzke R, Bekjarova A, Spiekerkoetter E: Bosentan treatment in patients with primary pulmonary hypertension receiving non-parenteral prostaglandins. Am J Respir Crit Care Med 2003; 167: A275.
17. Humbert M, Barst RJ, Robbins IM, Channick R, Manes A, Rubin LJ, Gali N, Boonstra A, Badesch D, Frost A, McLaughlin V, Simonneau G, Rich S: Safety and efficacy of Bosentan combined with epoprostenol in patients with severe pulmonary arterial hypertension. Am J Respir Crit Care Med 2003; 167: A441.